Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Wondering what credit card is good for travel points? Compare various options to find the best card that suits your travel needs.
17,761 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Palantir delivered an 85% year-over-year revenue surge in Q1 2026 and lifted full-year targets, but the shares are do...
This week's Sunday reads gather practical investing lessons you can act on. From patient investing to tax strategies,...
BigBear.AI delivers a stronger Q1 2026, expanding margins and backlog while signaling a ramp in defense contracts. Th...
As investors eye small-cap medical devices, Inogen's INGN 2026 earnings story matters. This analysis breaks down Q1 r...
Teads released its Q1 2026 results, showing resilience in a volatile ad market. This investor-focused guide breaks do...
A sizable move in the First Trust QTEC fund has traders buzzing. Is the sale a warning sign for overheated AI stocks ...
As CI&T launches into 2026, investors are scanning for momentum, margin resilience, and strategic bets. This deep div...
A new AI-driven forecast puts Solana on a trajectory to smash expectations by late 2026, driven by on-chain adoption ...
Cardano has struggled to deliver on big promises, leaving many investors looking for cryptocurrencies that better buy...
Bitcoin faced a sharp test as ETF-related outflows spiked, pushing BTC toward important support levels. Traders are w...
The 2025 GFLEC index shows no improvement in Americans’ financial literacy since 2017, with gaps by gender and race w...